DNLI Key Statistics, Chart & Performance
The current stock price of DNLI is 21.74 USD. In the past month the price increased by 31.68%. In the past year, price decreased by -6.7%.
DNLI Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to DNLI. When comparing the yearly performance of all stocks, DNLI is one of the better performing stocks in the market, outperforming 74.99% of all stocks.
DNLI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DNLI. While DNLI seems to be doing ok healthwise, there are quite some concerns on its profitability.
DNLI Financial Highlights
Over the last trailing twelve months DNLI reported a non-GAAP Earnings per Share(EPS) of -2.91. The EPS decreased by -1.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -41.07% | ||
| ROE | -46.63% | ||
| Debt/Equity | 0.01 |
DNLI Forecast & Estimates
24 analysts have analysed DNLI and the average price target is 33.24 USD. This implies a price increase of 52.87% is expected in the next year compared to the current price of 21.74.
For the next year, analysts expect an EPS growth of -14.31% and a revenue growth -87.68% for DNLI
DNLI Ownership
About DNLI
Company Profile
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. The company is headquartered in South San Francisco, California and currently employs 517 full-time employees. The company went IPO on 2017-12-08. The firm is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. The company has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). The company is also exploring programs in oncology, inflammation, and other diseases.
Company Info
DENALI THERAPEUTICS INC
161 Oyster Point Blvd.
South San Francisco CALIFORNIA 94080 US
CEO: Ryan J. Watts
Employees: 517
Phone: 16508668547
DENALI THERAPEUTICS INC / DNLI FAQ
What does DENALI THERAPEUTICS INC do?
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. The company is headquartered in South San Francisco, California and currently employs 517 full-time employees. The company went IPO on 2017-12-08. The firm is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. The company has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). The company is also exploring programs in oncology, inflammation, and other diseases.
Can you provide the latest stock price for DENALI THERAPEUTICS INC?
The current stock price of DNLI is 21.74 USD. The price increased by 0.69% in the last trading session.
Does DENALI THERAPEUTICS INC pay dividends?
DNLI does not pay a dividend.
How is the ChartMill rating for DENALI THERAPEUTICS INC?
DNLI has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is DENALI THERAPEUTICS INC (DNLI) expected to grow?
The Revenue of DENALI THERAPEUTICS INC (DNLI) is expected to decline by -87.68% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the ownership structure of DENALI THERAPEUTICS INC (DNLI)?
You can find the ownership structure of DENALI THERAPEUTICS INC (DNLI) on the Ownership tab.
What is the Short Interest ratio of DENALI THERAPEUTICS INC (DNLI) stock?
The outstanding short interest for DENALI THERAPEUTICS INC (DNLI) is 11.09% of its float.